Cited by 410Pain Mechanisms and TreatmentsPain Management and TreatmentCancer Treatment and Pharmacology

Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management

Open access
Tesfaye, S., Vileikyte, L., Rayman, G., Sindrup, S. H., Perkins, B. A., Baconja, M., Vinik, A. I., Boulton, A. J. M. +1 more·2011·Diabetes/Metabolism Research and Reviews

Abstract

Painful diabetic peripheral neuropathy (DPN) is common, is associated with significant reduction in quality of life and poses major treatment challenges to the practising physician. Although poor glucose control and cardiovascular risk factors have been proven to contribute to the aetiology of DPN, risk factors specific for painful DPN remain unknown. A number of instruments have been tested to assess the character, intensity and impact of painful DPN on quality of life, activities of daily living and mood. Management of the patient with DPN must be tailored to individual requirements, taking into consideration the co‐morbidities and other factors. Pharmacological agents with proven efficacy for painful DPN include tricyclic anti‐depressants, the selective serotonin and noradrenaline re‐uptake inhibitors, anti‐convulsants, opiates, membrane stabilizers, the anti‐oxidant alpha‐lipoic acid and topical agents including capsaicin. Current first‐line therapies for painful DPN include tricyclic anti‐depressants, the serotonin and noradrenaline re‐uptake inhibitor duloxetine and the anti‐convulsants pregabalin and gabapentin. When prescribing any of these agents, other co‐morbidities and costs must be taken into account. Second‐line approaches include the use of opiates such as synthetic opioid tramadol, morphine and oxycodone‐controlled release. There is a limited literature with regard to combination treatment. In extreme cases of painful DPN unresponsive to pharmacotherapy, occasional use of electrical spinal cord stimulation might be indicated. There are a number of unmet needs in the therapeutic management of painful DPN. These include the need for randomized controlled trials with active comparators and data on the long‐term efficacy of agents used, as most trials have lasted for less than 6 months. Finally, there is a need for appropriately designed studies to investigate non‐pharmacological approaches. Copyright © 2011 John Wiley & Sons, Ltd.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/dmrr.1225

Cites

59 of 59 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Other diabetic neuropathies include mononeuritis such as cranial nerve palsies and entrapment neuropathies.

    “Other forms of diabetic neuropathies are mononeuritis such as cranial nerve palsies or entrapment neuropathies (eg, carpal tunnel syndrome, ulnar entrapment, and peroneal entrapment, among others).632–635”

    From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [633]

    The Introduction (p. 2) describes entrapments as conditions that can masquerade as neuropathy, rather than as forms of diabetic neuropathy. The assessment section (p. 3) likewise says to exclude entrapment syndromes when diagnosing painful diabetic peripheral neuropathy. The cited passages do not address cranial nerve palsies or the named entrapment examples. (LLM, conf=0.75)

    Checked by a reasoning model — may be wrong.

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 3

  1. [24]24. Boulton AJM, Vinik AI, Arezzo JC, et al . Diabetes neuropathies: a statement by the American Diabetes Association. Diabetes Care 2005; 28: 1-7.
  2. [39]39. Backonja MM, Beydoun A, Edwards KR, et al . Gabapentin for symptomatic treatment of painful neuropathy in patients with diabetes mellitus. JAMA 1998; 280: 1831-1836.
  3. [43]43. Jarvis B, Coukell AJ. Mexilitene: a review of its therapeutic use in painful diabetic neuropathy. Drugs 1998; 56: 691-708.

Cited by

Sorted by citations

Authors
Tesfaye, S., Vileikyte, L., Rayman, G., Sindrup, S. H., Perkins, B. A., Baconja, M., Vinik, A. I., Boulton, A. J. M., & Neuropathy, O. B. O. T. T. E. P. O. D.
Affiliations
  • Royal Hallamshire Hospital (GB)
  • Ipswich Hospital (GB)
  • Odense University Hospital (DK)
  • University of Toronto (CA)
  • University of Wisconsin–Madison (US)
  • Eastern Virginia Medical School (US)
  • University of Manchester (GB)
Corresponding author
Boulton, A. J. M.
Venue
Diabetes/Metabolism Research and Reviews
Publisher
Wiley
Published
2011-10
Volume
27
Issue
7
Pages
629-638
ISSN
  • 1520-7552 (ISSN-L)
  • 1520-7560
OpenAlex
W2008600729
Cited by
410
References
59
Citations by year
2026: 15 · 2025: 13 · 2024: 21 · 2023: 31 · 2022: 42 · 2021: 37 · 2020: 31 · 2019: 33 · 2018: 34 · 2017: 21 · 2016: 23 · 2015: 31 · 2014: 35 · 2013: 29 · 2012: 12
FWCI
16.73
Type
journal article
Language
en
Open access
Locations
  • Diabetes/Metabolism Research and Reviews (publishedVersion)
  • PubMed (publishedVersion)
  • University of Southern Denmark Research Portal (University of Southern Denmark) (publishedVersion)
Topics
  • Health Sciences › Medicine › Physiology › Pain Mechanisms and Treatments
  • Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Treatment
  • Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
Keywords
diabetic neuropathic pain, neuropathic pain, diabetes mellitus, quality of life, pain assessment, tricyclic antidepressants, duloxetine, pregabalin, gabapentin, antiepileptic drugs, opiates, tramadol, spinal cord stimulation, alpha-lipoic acid, capsaicin, combination therapy, pharmacological management
MeSH terms
Activities of Daily Living, Analgesics, Anticonvulsants, Antidepressive Agents, Diabetic Neuropathies, Humans, Pain, Quality of Life, Disease Management, Consensus

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review